Senior Scientist, Translational Biomarker Discovery

The Jounce Translational Science Platform is key to our understanding of tumor immunobiology and is instrumental in our approach to identifying and prioritizing targets and developing biomarker strategies to enable us to select the right patients for our cancer immunotherapeutics.  We are seeking a strong scientist to join a translational team at Jounce focused on biomarker discovery and validation. The successful candidate will be responsible for identification and hands-on execution of novel biomarker strategies for multiple biologics programs in the Jounce pipeline, and will manage a team of 2 associates with a focus on using flow cytometry and ex vivo tumor histoculture technologies. This individual will oversee the design, development, and conduct of experiments aimed at characterizing expression of key immune regulators molecules in tumors; and will be expected to expand upon the existing tumor histoculture methods in-house, developing novel 3D model systems to assess molecular responses to our therapeutic molecules for use as potential biomarkers during the drug development process.  The successful applicant will play a key team role in contributing to the design of, and hands-on support for, biomarker and differentiation strategies for Jounce programs ranging from the early discovery to clinical development stage. The position will report in to the Director of Translational Sciences.

Responsibilities

  • Directly manage 2 associate level individuals.
  • Work in cross-functional teams to help identify and execute on translational biomarker plans for programs spanning discovery and validation through early clinical development.
  • Characterize and quantify expression of immune regulatory molecules in multiple human tumor samples, and mouse syngeneic tumor samples, using flow cytometry.
  • Generate translational data using ex-vivo 3D culture systems to assess molecular responses to Jounce’s immunotherapeutics to further increase understanding of mechanism of action as well as to identify potential biomarkers for assessment during clinical development.
  • Develop RNA and cytokine based response assessment for immunotherapies in ex-vivo culture systems.
  • Data analysis, thorough documentation of the work, and clear communication of results in group and leadership settings.
  • Work closely with discovery scientists and other members of the larger Translational Science effort, particularly the bioinformatics/RNA-based team, to support translational biomarker efforts across programs from early preclinical to clinical stage.
  • Manage key collaborations (with academics and external CRO’s) to support Translational Sciences Platform development.
  • Define novel mechanisms of resistance to immunotherapies by studying tumors at relapse using syngeneic tumor models and human tumor samples from patients.

Qualifications:

  • Doctoral degree (PhD) in Immunology/Tumor Biology or related field with post-doctoral experience and 1- 4+ years of relevant academic/industry experience.
  • Will consider a Masters or Bachelor’s degree with substantial (>10 years) of relevant industry experience in a biomarker/translational science setting and management experience.
  • Track record in managing, mentoring and developing junior level reports.
  • Significant hands on experience with either ex-vivo organ culture methods, or flow-cytometry of immune cell subsets preferably from tumor samples (human and/or mouse).
  • Strong understanding of the utility of translational science-driven biomarker approaches to enable drug development.
  • Experience working in cross functional program teams with proven ability to collaborate and work effectively in a matrix environment.
  • Excellent oral and written communication skills, including communication with internal and external colleagues and research leadership and good organizational skills.
  • Ability to multi-task and excel in a fast-paced environment.

Preferred:

  • Specific experience in immuno-oncology particularly with biologics (e.g monoclonal antibody therapies) an advantage.
  • Direct experience in using biomarker-driven translational science and personalized medicine strategies to enable drug development an advantage.
  • Experience interacting with academic preclinical and clinical collaborators in Immuno-oncology is a plus.